Skip to main content
OpenTrials
Recruiting

NCT Number: NCT00373841

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF)

The purpose of the study is to identify genetic and biologic markers that may predict the loss of lung function due to idiopathic pulmonary fibrosis. The studies will compare genetic and biologic markers of samples to changes in symptoms. The ultimate goal is to predict if or when patients are likely to experience a rapid decline in lung function due to disease progression.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Michelle F MacPherson

Pittsburgh, Pennsylvania, 15213, United States

Location status: Recruiting

Location contact

Daniel J. Kass, M.D.

SUB_INVESTIGATOR

Daniel Sullivan, MD

SUB_INVESTIGATOR

Eleanor Valenzi, MD

SUB_INVESTIGATOR

Gillian Goobie, MD PhD

SUB_INVESTIGATOR

John Sembrat, PhD

SUB_INVESTIGATOR

Kevin F Gibson, MD

PRINCIPAL_INVESTIGATOR

Kristen Veraldi, M.D.

SUB_INVESTIGATOR

Luis Ortiz, MD

SUB_INVESTIGATOR

Michelle F MacPherson, MAT

CONTACT

[email protected]

14126474537

Michelle F. MacPherson, BS, MAT

SUB_INVESTIGATOR

Michelle L Meyers, BSN RN

CONTACT

[email protected]

412-692-2149

Michelle Meyers, BSN, RN

SUB_INVESTIGATOR

Morgan L Carnahan, BS

SUB_INVESTIGATOR

Prabhir Ray, PhD

SUB_INVESTIGATOR

Seyed Mehdi Nouraie, MD

SUB_INVESTIGATOR

Timothy Corcoran, PhD

SUB_INVESTIGATOR

Xiaoping Chen, MS

SUB_INVESTIGATOR

Xiaoyun Li, MD

SUB_INVESTIGATOR

Yingze Zhang, PhD

SUB_INVESTIGATOR

About this study

People who are diagnosed with idiopathic pulmonary fibrosis are asked to participate in this study. The subject must be treated at the Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease. Subjects, if consented, are required to perform tests so that research data can be collected. At the initial visit, patients are subject to having a blood draw, pulmonary function testing, echocardiograms, and CT scans as well as completing several questionnaires designed to measure how the patient is feeling. Follow up visits are then scheduled in 3-4 month intervals. Every 3-4 months blood samples will be collected while every 6-8 months the questionnaires will administered. If the patient enters a stage of accelerated decline in lung function, a bronchoscopy will be performed to collect residual bronchoalveolar lavage fluid for testing. All of the results of clinical and laboratory testing will be placed into the subjects research file.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are 18 or older
  • Diagnosis of Idiopathic Pulmonary Fibrosis
  • Treated at the Simmons Center

Exclusion criteria

  • Other Lung Illness

Study contacts

Contact information is provided by the study sponsor or research team.

Michelle MacPherson, MAT

CONTACT

[email protected]

412-647-4537

Michelle Meyers, BSN RN

CONTACT

[email protected]

412-692-2149

Sponsors and collaborators

Lead sponsor

University of Pittsburgh

Other

Registry information

Official study title

Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis

Acronym: GAP

Important dates

Study start
2005
Primary completion
2030
Study completion
2030
First posted
Sep 8, 2006
Registry last updated
Oct 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.